These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 2205379)

  • 41. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
    Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
    Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
    Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
    Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
    Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
    Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S
    Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG; Hess A; Lucas DM; O'Donnell P; Ambinder RF; Diehl LF; Carter-Brookins D; Newton S; Flinn IW
    Clin Cancer Res; 2007 Apr; 13(8):2392-9. PubMed ID: 17438098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
    Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
    Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK; Anderson TD; Hayes TJ
    J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y; Umesaki N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S; Flanagan P; Blackinton D; Wanebo H
    Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
    Fujiwara T; Grimm EA
    J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C; Hank JA; Albertini MR; Borchert AA; Moore KH; Schiller JH; Bechhofer R; Borden EC; Storer B; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):43-8. PubMed ID: 8435431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.